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Background: The combined effect of microalbuminuria (MICRO) and metabolic syndrome (METS) on cardiovascular disease outcomes and 
mortality in the non-diabetic population is ill defined.
Methods: The study comprised 6814 asymptomatic men and women (52.85%), aged 45-84 yrs without prior cardiovascular disease, enrolled in the 
Multi-Ethnic Study of Atherosclerosis. Urine albumin creatinine ratio was measured in all participants at study enrollment. Participants were divided on 
the basis of presence/absence of METS (National Cholesterol Education Program definition) and MICRO (30-300 mg/g) into 4 groups: 1) No METS + No 
MICRO (reference group) [70%] 2) MICRO-only [4%] 3) METS-only [23.3%] 4) METS+MICRO [2.7%]. Cox proportional hazard modeling with adjustments 
was used to test association with all cause mortality, all cardiovascular events (CVDA), myocardial infarction (MI) and stroke.
Results: Of the 5907 non-diabetic individuals included in this analysis, 26% had METS. Prevalence of MICRO was 10.53% and 4.81% respectively 
in the METS and non-METS population. A total of 175 deaths, 235 CVDA events, 81 MIs and 62 strokes were noted over a mean follow up of 4.6 
years. The METS+MICRO group showed a stronger association with most measured end points as compared to the METS-only group (Table 1).
Conclusion: Microalbuminuria in non-diabetic patients with metabolic syndrome predicts higher cardiovascular morbidity and all cause mortality 
compared to metabolic syndrome alone regardless of ethnic Background:  
Crude and adjusted hazard ratio (HR) estimates associated with metabolic syndrome and microalbuminuria
Death (n=175) CVDA (n = 235) MI (n=81) Stroke (n = 62)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
A. Unadjusted HR (n)
MICRO only (235) 3.99 (2.52-6.33)* <.0001 1.47 (0.77-2.80) 0.241 0.40 (0.06-2.93) 0.369 3.45 (1.44-8.26)* 0.005
METS only (1377) 1.01 (0.69-1.49) 0.951 1.94 (1.46-2.58)* <.0001 1.84 (1.14-2.96)* 0.013 1.73 (0.97-3.08) 0.063
MICRO+METS (162) 3.23 (1.78-5.87)* 0.0001 4.3 (2.65-6.97)* <.0001 4.29 (1.94-9.52)* 0.0003 4.31 (1.68-11.06)* 0.002
B. Adjusted for age, gender and ethnicity
MICRO only 2.61 (1.64-4.15)* <.0001 1.06 (0.56-2.03) 0.851 0.31 (0.04-2.25) 0.247 2.29 (0.95-5.51) 0.065
METS only 0.99 (0.67-1.47) 0.9672 2.04 (1.53-2.71) <.0001 2.04 (1.26-3.29)* 0.004 1.59(0.89-2.85) 0.116
MICRO+METS 1.91 (1.04-3.50)* 0.037 3.06 (1.88-4.99) <.0001 3.33 (1.49-7.47)* 0.004 2.38 (0.91-6.20) 0.076
C.
Adjusted for above variables and known 
confounders†
MICRO only 2.77 (1.74-4.43)* <.0001 1.09 (0.57-2.08) 0.806 0.31 (0.04-2.26) 0.248 2.49 (1.03-6.06)* 0.044
METS only 1.00 (0.68-1.48) 0.99 2.07 (1.55-2.75)* <.0001 1.99 (1.24-3.23)* 0.005 1.73 (0.96-3.13) 0.071
MICRO+METS 1.78 (0.94-3.35) 0.074 3.03 (1.85-4.96)* <.0002 3.29 (1.46-7.41)* 0.004 2.48 (0.94-6.53) 0.067
 CVDA- Myocardial infarction, Resuscitated Cardiac Arrest, Definite Angina, Probable Angina (if followed by Revascularization), Stroke, Stroke Death, Coronary Heart Disease Death, 
Other Atherosclerotic Death, Other Cardiovascular Disease related Death. * Statistically significant (p < 0.05) †Adjusted in addition for Smoking, Family history of cardiovascular 
disease, Low density lipoprotein, Antihypertensive medications, Statin therapy, and serum creatinine.
